Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 43, 2017, Pages 11488-11493

  Thamphiwatana, Soracha ^a,b   Angsantikul, Pavimol ^a,b   Escajadillo, Tamara ^c,d   Zhang, Qiangzhe ^a,b   Olson, Joshua ^c,d   Luk, Brian T ^a,b   Zhang, Sophia ^a,b   Fang, Ronnie H ^a,b   Gao, Weiwei ^a,b   Nizet, Victor ^c,d   Zhang, Liangfang ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Biomimetic nanoparticle; Detoxification; Lipopolysaccharide; Proinflammatory cytokine; Sepsis

Indexed keywords

CYTOKINE; ENDOTOXIN; GAMMA INTERFERON; INTERLEUKIN 6; NANOPARTICLE; TUMOR NECROSIS FACTOR; LIPOPOLYSACCHARIDE; LIPOPROTEIN; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; ESCHERICHIA COLI INFECTION; HUMAN; HUMAN CELL; HUVEC CELL LINE; J774 CELL LINE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SURVIVAL; ANIMAL; BACTEREMIA; CELL LINE; CELL MEMBRANE; CHEMISTRY; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; METABOLISM;

ANIMALS; BACTEREMIA; CELL LINE; CELL MEMBRANE; CYTOKINES; ENDOTOXINS; ESCHERICHIA COLI INFECTIONS; LIPOPOLYSACCHARIDES; LIPOPROTEINS; MACROPHAGES; MALE; MICE; MICE, INBRED ICR; NANOPARTICLES; SEPSIS; TOLL-LIKE RECEPTOR 4;

EID: 85032213635     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1714267114     Document Type: Article

References (40)

1. Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl JMed 369:840-851.
2. Cohen J (2002) The immunopathogenesis of sepsis. Nature 420:885-891.
3. Rittirsch D, Flierl MA, Ward PA (2008) Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8:776-787.
4. Ranieri VM, et al.; PROWESS-SHOCK Study Group (2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366:2055-2064.
5. Gaieski DF, Edwards JM, Kallan MJ, Carr BG (2013) Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 41:1167-1174.
6. Yaroustovsky M, et al. (2013) Prognostic value of endotoxin activity assay in patients with severe sepsis after cardiac surgery. J Inflamm (Lond) 10:8.
7. Grandel U, Grimminger F (2003) Endothelial responses to bacterial toxins in sepsis. Crit Rev Immunol 23:267-299.
8. Peters K, Unger RE, Brunner J, Kirkpatrick CJ (2003) Molecular basis of endothelial dysfunction in sepsis. Cardiovasc Res 60:49-57.
9. Wang Y (2014) Attenuation of berberine on lipopolysaccharide-induced inflammatory and apoptosis responses in beta-cells via TLR4-independent JNK/NF-κB path. Pharm Biol 52:532-538.
10. Nishio K, et al. (2013) Attenuation of lipopolysaccharide (LPS)-induced cytotoxicity by tocopherols and tocotrienols. Redox Biol 1:97-103.
11. Brandenburg K, Wiese A (2004) Endotoxins: Relationships between structure, function, and activity. Curr Top Med Chem 4:1127-1146.
12. Gabrielli L, et al. (2012) Recent approaches to novel antibacterials designed after LPS structure and biochemistry. Curr Drug Targets 13:1458-1471.
13. Kelesidis T, Falagas ME (2015) The safety of polymyxin antibiotics. Expert Opin Drug Saf 14:1687-1701.
14. Justo JA, Bosso JA (2015) Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 35:28-33.
15. Cavaillon JM (2011) Polymyxin B for endotoxin removal in sepsis. Lancet Infect Dis 11: 426-427.
16. Fujii T, et al. (2016) Polymyxin B-immobilised haemoperfusion and mortality in critically ill patients with sepsis/septic shock: A protocol for a systematic review and metaanalysis. BMJ Open 6:e012908.
17. Raghavan R (2012) When access to chronic dialysis is limited: One center's approach to emergent hemodialysis. Semin Dial 25:267-271.
18. Zhang L, Leroux JC (2015) Current and forthcoming approaches for systemic detoxification. Adv Drug Deliv Rev 90:1-2.
19. Hu CMJ, et al. (2015) Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526:118-121.
20. Hu CMJ, Fang RH, Copp J, Luk BT, Zhang L (2013) A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol 8:336-340.
21. Escajadillo T, Olson J, Luk BT, Zhang L, Nizet V (2017) A red blood cell membranecamouflaged nanoparticle counteracts Streptolysin O-mediated virulence phenotypes of invasive group a streptococcus. Front Pharmacol 8:477.
22. Copp JA, et al. (2014) Clearance of pathological antibodies using biomimetic nanoparticles. Proc Natl Acad Sci USA 111:13481-13486.
23. Pang Z, et al. (2015) Detoxification of organophosphate poisoning using nanoparticle bioscavengers. ACS Nano 9:6450-6458.
24. Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2:675-680.
25. Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol 1:135-145.
26. Schütt C (1999) Fighting infection: The role of lipopolysaccharide binding proteins CD14 and LBP. Pathobiology 67:227-229.
27. Triantafilou M, Triantafilou K (2002) Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 23:301-304.
28. Zanoni I, et al. (2011) CD14 controls the LPS-induced endocytosis of toll-like receptor 4. Cell 147:868-880.
29. Schilling JD, Machkovech HM, He L, Diwan A, Schaffer JE (2013) TLR4 activation under lipotoxic conditions leads to synergistic macrophage cell death through a TRIFdependent pathway. J Immunol 190:1285-1296.
30. Hagar JA, Powell DA, Aachoui Y, Ernst RK, Miao EA (2013) Cytoplasmic LPS activates caspase-11: Implications in TLR4-independent endotoxic shock. Science 341:1250-1253.
31. Martinon F, Chen X, Lee A-H, Glimcher LH (2010) TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat Immunol 11:411-418.
32. Spence S, et al. (2015) Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation. Sci Transl Med 7:303ra140.
33. Gratton SEA, et al. (2007) Nanofabricated particles for engineered drug therapies: A preliminary biodistribution study of PRINT nanoparticles. J Control Release 121:10-18.
34. Hu C-MJ, et al. (2011) Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA 108:10980-10985.
35. Unger RE, Peters K, Sartoris A, Freese C, Kirkpatrick CJ (2014) Human endothelial cellbased assay for endotoxin as sensitive as the conventional limulus amebocyte lysate assay. Biomaterials 35:3180-3187.
36. Roger T, et al. (2009) Protection from lethal gram-negative bacterial sepsis by targeting toll-like receptor 4. Proc Natl Acad Sci USA 106:2348-2352.
37. Kang JH, et al. (2014) An extracorporeal blood-cleansing device for sepsis therapy. Nat Med 20:1211-1216.
38. Fang RH, et al. (2013) Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale 5:8884-8888.
39. Dehaini D, et al. (2017) Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv Mater 29:1606209.
40. Fang RH, et al. (2014) Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett 14:2181-2188.